SUSQUEHANNA INTERNATIONAL GROUP, LLP - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 75 filers reported holding REVANCE THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 0.17 and the average weighting 1.6%.

Quarter-by-quarter ownership
SUSQUEHANNA INTERNATIONAL GROUP, LLP ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$4,873,224
-45.7%
424,867
+19.8%
0.00%
-100.0%
Q2 2023$8,975,888
-33.4%
354,638
-15.2%
0.00%
-33.3%
Q1 2023$13,472,315
-24.9%
418,265
-56.9%
0.00%
-25.0%
Q4 2022$17,934,222
+25.0%
971,518
+82.8%
0.00%0.0%
Q3 2022$14,353,000
+208.9%
531,581
+58.1%
0.00%
Q2 2022$4,646,000
-54.6%
336,244
-35.9%
0.00%
-100.0%
Q1 2022$10,226,000
+54.4%
524,437
+29.2%
0.00%
Q4 2021$6,622,000
+18.3%
405,806
+101.9%
0.00%
Q3 2021$5,599,000
+4.5%
200,988
+11.2%
0.00%
Q2 2021$5,359,000
-28.5%
180,807
-32.5%
0.00%
-100.0%
Q1 2021$7,490,000
-44.3%
267,968
-43.6%
0.00%0.0%
Q4 2020$13,454,000
+137.8%
474,726
+111.0%
0.00%0.0%
Q3 2020$5,657,000
+34.9%
225,027
+31.1%
0.00%0.0%
Q2 2020$4,193,000
+71.7%
171,684
+4.1%
0.00%0.0%
Q1 2020$2,442,000
-21.7%
164,981
-14.1%
0.00%
Q4 2019$3,119,000
+23.8%
192,132
-0.9%
0.00%
Q3 2019$2,520,000
-55.9%
193,796
-56.0%
0.00%
Q2 2019$5,712,000
+425.0%
440,273
+538.1%
0.00%
Q1 2019$1,088,000
+251.0%
69,000
+348.1%
0.00%
Q4 2018$310,000
-84.8%
15,400
-81.3%
0.00%
Q3 2018$2,044,000
-8.2%
82,258
+1.4%
0.00%
Q2 2018$2,226,000
-18.2%
81,100
-8.2%
0.00%
-100.0%
Q1 2018$2,720,000
-76.1%
88,300
-72.2%
0.00%
-75.0%
Q4 2017$11,369,000
+285.0%
318,005
+196.8%
0.00%
+300.0%
Q3 2017$2,953,000
+143.8%
107,162
+133.5%
0.00%
Q2 2017$1,211,000
+64.1%
45,900
+29.3%
0.00%
Q1 2017$738,000
+12.5%
35,500
+11.9%
0.00%
Q4 2016$656,000
+285.9%
31,714
+202.0%
0.00%
Q3 2016$170,000
-60.6%
10,500
-66.9%
0.00%
Q2 2016$431,000
-75.1%
31,700
-68.0%
0.00%
Q1 2016$1,729,000
-75.2%
98,981
-51.4%
0.00%
-100.0%
Q4 2015$6,959,000
+129.3%
203,713
+99.7%
0.00%
Q3 2015$3,035,000
+153.1%
101,989
+172.1%
0.00%
Q2 2015$1,199,000
+33.8%
37,484
-13.2%
0.00%
Q1 2015$896,000
+155.3%
43,200
+318.2%
0.00%
Q2 2014$351,00010,3310.00%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q3 2016
NameSharesValueWeighting ↓
Essex Woodlands Management, Inc. 3,342,047$94,714,00024.58%
Palo Alto Investors LP 2,673,313$75,762,0003.97%
Evolutionary Tree Capital Management, LLC 89,348$2,532,0001.93%
RICE HALL JAMES & ASSOCIATES, LLC 1,121,152$31,773,0001.12%
ArrowMark Colorado Holdings LLC 2,964,135$84,004,0000.65%
Rhenman & Partners Asset Management AB 220,000$6,235,0000.51%
Fosun International Ltd 233,841$6,627,0000.43%
OSTERWEIS CAPITAL MANAGEMENT INC 174,970$4,959,0000.30%
ESSEX INVESTMENT MANAGEMENT CO LLC 76,671$2,173,0000.27%
Tekla Capital Management LLC 213,808$6,059,0000.21%
View complete list of REVANCE THERAPEUTICS INC shareholders